Sounds cautiously promising.

------------------------------------------------------------------------------------


Addex Pharmaceuticals said its lead product, ADX10059, which is nearing completion of Phase IIb testing in gastroesophageal reflux disease and migraine prevention, also has demonstrated significant potential in a non-human primate model of Parkinson's disease levodopa induced dyskinesia. In a recently completed study, all doses of ADX10059 abolished levodopa induced dyskinesia in the first hour after levodopa administration. There was no adverse effect on Parkinsonian disability scoring. PD-LID currently has no approved therapy and there are an estimated 1.2 million patients with PD-LID in the U.S.

http://www.marketwatch.com/story/add...ial-2009-09-14